- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.05. | CalciMedica GAAP EPS of -$0.36 misses by $0.06 | 1 | Seeking Alpha | ||
| CALCIMEDICA Aktie jetzt für 0€ handeln | |||||
| 14.05. | CalciMedica, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | CalciMedica, Inc.: CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates | 66 | PR Newswire | Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025
Presentations at... ► Artikel lesen | |
| 01.04. | H.C. Wainwright maintains $16 target on CalciMedica stock | 4 | Investing.com | ||
| 27.03. | CalciMedica, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | CalciMedica, Inc.: CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates | 406 | PR Newswire | Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025
Post-hoc analysis... ► Artikel lesen | |
| 27.03. | CalciMedica, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.03. | CalciMedica secures credit facility for up to $32.5M | 1 | Seeking Alpha | ||
| 05.03. | CalciMedica sichert sich Kreditfazilität in Höhe von 32,5 Millionen US-Dollar | 2 | Investing.com Deutsch | ||
| 04.03. | CalciMedica reports reduced mortality in AKI trial with Auxora | 1 | Investing.com | ||
| 04.03. | CalciMedica, Inc. (CALC): Among Penny Stocks with Insider Buying in 2025 | 1 | Insider Monkey | ||
| 04.03. | CalciMedica, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.01. | CalciMedica beruft neuen Direktor | 1 | Investing.com Deutsch | ||
| 14.01. | CalciMedica appoints new director amid clinical trials | 2 | Investing.com | ||
| 14.01. | CalciMedica, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.12.24 | CalciMedica, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.24 | CalciMedica, Inc.: CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates | 153 | PR Newswire | Additional positive data, including a win ratio analysis, announced from CARPO Phase 2b trial of Auxora in acute pancreatitis (AP); Company expects to be in a position... ► Artikel lesen | |
| 12.08.24 | CalciMedica, Inc.: CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates | 624 | PR Newswire | Positive topline data announced from CARPO, Phase 2b trial of Auxora in acute pancreatitis (AP); additional data to be presented at a medical meeting later this year
First patient enrolled in KOURAGE... ► Artikel lesen | |
| 09.07.24 | CalciMedica, Inc.: CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora in Severe Acute Kidney Injury (AKI) | 215 | PR Newswire | Development of Auxora in AKI is supported by both clinical and pre-clinical evidence
Topline data expected in 2025
LA JOLLA, Calif., July 9, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica"... ► Artikel lesen | |
| 27.06.24 | CalciMedica, Inc.: CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora in Acute Pancreatitis (AP) | 260 | PR Newswire | Primary objective of the trial met with statistically significant dose response with up to 43.6% relative reduction (2.1 day improvement) in median time to solid food tolerance versus placebo in hyper-inflamed... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 99,30 | +1,85 % | Rheinmetall nicht zu bremsen! Evotec LEERVERKAUFT! Paukenschlag bei Vidac Pharma! Und was macht BioNTech Aktie? | Paukenschlag bei Vidac Pharma. Der Biotech-Highflyer des vergangenen Jahres hat starke Ergebnisse zu seinem Krebsmedikament veröffentlicht. Um 5 % ging es immerhin gestern nach oben. Ist die Konsolidierung... ► Artikel lesen | |
| CUREVAC | 3,934 | +0,82 % | CureVac mit SPEZIAL-MELDUNG: Insider kaufen massenhaft Anteile - Das dürfen Sie nicht verpassen! | ||
| MODERNA | 24,010 | -1,62 % | Moderna: Regierungs-Ärger bei Vogelgrippe-Impfstoff | Moderna hat Zwischenergebnisse aus einer Phase-1/2-Studie zu seinem Pandemie-Impfstoff mRNA-1018 gegen die H5-Vogelgrippe vorgestellt. Demnach erzielte der mRNA-Kandidat des US-Konkurrenten von BioNTech... ► Artikel lesen | |
| AMGEN | 252,20 | +0,28 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
| NOVAVAX | 6,251 | -0,16 % | Schock-News für Novavax Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
| STRYKER | 335,60 | +0,12 % | Former Intuitive, Stryker VP joins Think Surgical as EVP to advance surgical robot tech | ||
| BIOGEN | 116,85 | +1,08 % | DAX tritt auf der Stelle - Nvidia & Biogen mit Überraschung! Gold, EUR & Aktien im Chartcheck | ||
| ILLUMINA | 73,28 | +0,54 % | Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain? | ||
| MAINZ BIOMED | 2,775 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed gibt Interim-Ergebnisse seiner klinischen Studie eAArly DETECT 2 bekannt | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed gibt Interim-Ergebnisse seiner klinischen Studie eAArly DETECT 2 bekannt
16.05.2025 /... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,800 | +0,63 % | Could Viking Therapeutics Become the Next Eli Lilly? | ||
| INTELLIA THERAPEUTICS | 6,774 | +0,83 % | Canaccord Genuity lowers Intellia stock price target to $54 | ||
| BIOCRYST PHARMACEUTICALS | 9,610 | -0,52 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| TEMPUS AI | 54,68 | -0,62 % | XFRA NEW INSTRUMENTS AVAILABLE ON 03.06.2025 | The following instruments on XETRA do have their first trading 03.06.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 03.06.2025
Aktien
1 US88023B1035 Tempus AI Inc.
2 KYG9482E1180... ► Artikel lesen | |
| IDEXX LABORATORIES | 460,60 | +0,15 % | Jim Cramer on IDEXX Laboratories, Inc. (IDXX): "I Just Can't Get My Arms Around It" | ||
| SAREPTA THERAPEUTICS | 34,950 | +0,81 % | FDA Grants Platform Technology Status To Sarepta's RAAVrh74 Vector | WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT), Wednesday announced that the FDA has designated its rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 for limb-girdle... ► Artikel lesen |
CALCIMEDICA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,700 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CALCIMEDICA INC finden Sie auf Wallstreet Online.